
Peer reviewed version

Link to published version (if available):
10.1183/13993003.00825-2019

Link to publication record in Explore Bristol Research
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via European Respiratory Society at https://erj.ersjournals.com/content/early/2019/06/12/13993003.00825-2019.article-info. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Epstein-Barr virus in pleural effusions: protagonist or pretender?

David T Arnold¹, Tim Suri², Fergus Hamilton³, Anna Morley¹, Andrew Medford¹, Ian B Vipond⁴, Peter Muir⁴, Nick A Maskell¹.

1. Academic Respiratory Unit, School of Translational Health Sciences, University of Bristol.
2. School of Cellular and Molecular Medicine, University of Bristol.
3. Department of Microbiology, North Bristol NHS Trust.

Corresponding author- David Arnold, Level 2, Learning and Research Building, Southmead Hospital, Bristol, United Kingdom, BS10 5NB.
Introduction

Unilateral pleural effusions are a common diagnostic challenge for the respiratory physician. In the majority a diagnosis can be made after medical history, computerised tomography (CT) and pleural fluid analysis [1]. A proportion of patients will require a pleural biopsy but following this a minority will remain undiagnosed and are defined as idiopathic/inflammatory pleuritis (IP) [2]. These patients often require extended follow up to ensure effusion resolution and exclude malignancy.

A previous prospective study proposed a possible causative role of Epstein-Barr virus (EBV) in “unexplained” pleural effusions after finding that nearly 60% had evidence of EBV-DNA within the pleural fluid [3].

This hypothesis has not been validated in an external cohort. Our aim was to determine the presence and quantity of EBV in the pleural fluid and serum of patients with ‘undiagnosed’ pleural effusions compared to controls.

Methods

Patients

Patients presenting with undiagnosed pleural effusions were prospectively recruited to this single centre UK based observational study and consented to having serum and pleural fluid stored. All were assigned a 12-month diagnosis as to the most likely cause of their effusion. The final diagnosis was agreed by two independent respiratory consultants. A diagnosis of IP required histocytological evidence (biopsy negative for malignancy), in the absence of markers of infection (significantly raised white blood cells or C-reactive protein) or a known history of asbestos exposure (to exclude cases of parapneumonic effusion or benign asbestos related pleural effusions respectively). The full diagnostic criteria used in the study have been previously published [4].

Patients with final diagnosis of IP had pleural fluid and serum analysed for the presence of EBV. A selection of controls, matched by presentation date, of transudative effusions (cardiac, liver or renal failure) and parapneumonic effusions were also analysed.

DNA isolation and PCR

Samples were stored in a -70-degree freezer and analysed en-bloc. Nucleic acids were extracted from pleural fluid and serum using the Qiagen DSP virus/pathogen extraction kit according to
manufacturer instructions (Qiagen, Dusseldorf, Germany). In-house real time PCR was performed (in duplicate) using nucleic acid extracts spiked with T4 phage as internal control, TaqMan Fast Universal PCR Master Mix, and in-house EBV primers [5]. EBV-DNA levels were estimated from the crossing threshold (Ct value) at which DNA amplification became detectable (the limit of detection is about is approximately 1000 copies/mL).

Serology

EBV serology was performed using the DiaSorin LIAISON© XL platform, testing for anti-EBV antibodies using the EBV IgM, VCA IgG (Epstein-Barr virus capsid antigen), EBNA IgG (Epstein-Barr virus nuclear antigen) reagents.

Statistical analysis

Continuous data are expressed as medians (with ranges) and compared using a Mann-Whitney U-test. Non-continuous data was analysed using Fisher’s exact test. p<0.05 was used to define significance.

Results

Between 2008-2017, 1005 consecutive patients with a new pleural effusion were enrolled and had a 12-month diagnosis. IP was diagnosed in 27 cases (3%). The median age was 70 years (range 53-92) and there was a male predominance (23/27, 85%), see Table 1. The presence of EBV was assessed in these and 163 controls (54 transudates, 109 parapneumonic effusions). EBV-DNA was found in the pleural fluid of 14.8% (4/27) of IP cases compared to 13.8% (15/109) parapneumonic and 5.6% (3/54) transudative effusions. Ct values across all groups were high ranging from 33.8 to 41.2, indicating the presence of low levels of EBV-DNA. There was no significant difference in pleural fluid EBV levels depending on effusion aetiology or predominant cell types (p=0.183 and p=0.248 respectively, using Mann-Whitney U-test). The analysis was repeated using the qualitative EBV PCR results with no relationship found between the same groups (p=0.354 and p=0.701 respectively, using Fisher’s exact test).

Serological testing and serum EBV PCR was performed for cases where pleural fluid EBV-DNA was detected. All cases showed evidence of past EBV infection; none had detectable EBV IgM. On PCR,
EBV-DNA was found in low levels in the serum of 5 cases, all of whom had a final diagnosis of parapneumonic effusion.

Discussion

This study did not find evidence of EBV as a causative factor in the development of IP. A previous cohort study published by Thijsen in the European Respiratory Journal found EBV-DNA in the pleural fluid of 40% of a 60-patient cohort with all-cause effusions [3]. The prevalence of positive pleural fluid EBV-DNA was higher in the 34 patients with ‘unexplained’ pleural effusions. This prompted the authors to suggest that EBV reactivation might have a causative role in their development. This current study attempted to validate these findings using a 190 patient cohort in whom IP was only diagnosed after a biopsy and 12 months of radiological follow up.

EBV or human herpesvirus 4 infections are very common and by adulthood around 90% of individuals have been infected [6]. Acute infection is usually asymptomatic in the immunocompetent or can manifest itself as infectious mononucleosis. Following the acute phase, B lymphocytes become latently infected and EBV can persist with low/intermittent virion production. Reactivation within the lung can occur usually resulting from immunosuppression. A series of 20 cases of EBV-DNA-positive pleural effusions was published by Takei and colleagues [7]. All cases had a history of lung transplantation but EBV loads were relatively low.

EBV as a possible causative agent in pleural effusions is a plausible concept for a number of reasons. Firstly, some effusions will remain undiagnosed despite conventional histocytological investigations. Secondly, those presenting with pleural effusions might be immunocompromised due to age and/or immunosuppressive medications. Finally, the course of exudative effusions can be relapsing and remitting suggesting a reactivating viral process.

We examined a cohort of patients in whom the diagnosis was elusive despite pleural fluid analysis, imaging follow-up and histological biopsy. These patients were termed as having IP (literature terms include idiopathic, inflammatory, non-specific or fibrous pleuritis) and require fastidious follow up to exclude malignancy. Previous retrospective studies have found that 12-18% of cases of IP at initial biopsy have an underlying malignant cause [8, 9]. Identifying the other causes would be extremely useful for risk stratification. In this study, patients were diagnosed with IP after at least 1 year of follow up, no known history of asbestos exposure (to exclude benign asbestos pleural effusions), and a non-diagnostic pleural biopsy result. All cases were stable or resolved at 1 year and are therefore truly idiopathic.
In 15% of the IP cases, EBV was present within pleural fluid but at only very low levels. This prevalence was not significantly different to the infected or transudative controls. Additionally, there was no serological evidence of recent or reactivated EBV in cases with pleural fluid positive for EBV. We hypothesize that the low-levels of EBV DNA found in these pleural fluid samples may be a result of latently infected B lymphocytes without a pathological role.

In conclusion, we found no evidence that EBV was a causative factor in cases of IP and testing for EBV in these cases is unlikely to be diagnostic.
Table 1- Patient demographics

<table>
<thead>
<tr>
<th></th>
<th>Idiopathic pleuritis (n= 27)</th>
<th>Parapneumonic (n= 109)</th>
<th>Transudates (n= 54)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age (range)</td>
<td>68 (53-92)</td>
<td>63 (18-95)</td>
<td>78 (55-97)</td>
</tr>
<tr>
<td>Male/Female (n)</td>
<td>23/4</td>
<td>70/39</td>
<td>32/22</td>
</tr>
<tr>
<td>Median duration of symptoms in months (range)</td>
<td>3 (0.2-12)</td>
<td>0.2 (0.1-3)</td>
<td>4 (0.1-24)</td>
</tr>
<tr>
<td>Laterality (R/L/Bilateral)</td>
<td>18 / 7 / 2</td>
<td>57/ 44 / 8</td>
<td>31/ 6 / 17</td>
</tr>
<tr>
<td>Mean CRP mg/L (range)</td>
<td>17 (1-70)</td>
<td>145 (8-429)</td>
<td>24 (1-75)</td>
</tr>
<tr>
<td>Pleural fluid analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Lymphocytic</td>
<td>14 (52%)</td>
<td>18 (17%)</td>
<td>22 (41%)</td>
</tr>
<tr>
<td>• Neutrophilic</td>
<td>0 (0%)</td>
<td>58 (53%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>• Eosinophilic</td>
<td>6 (22%)</td>
<td>8 (7%)</td>
<td>4 (7%)</td>
</tr>
<tr>
<td>• Mixed</td>
<td>7 (26%)</td>
<td>25 (23%)</td>
<td>28 (52%)</td>
</tr>
<tr>
<td>Mean pleural fluid protein g/L (range)</td>
<td>44 (24-59)</td>
<td>43 (17-68)</td>
<td>23 (12-31)</td>
</tr>
<tr>
<td>Presence of pleural fluid EBV-DNA</td>
<td>4/27 (14.8%)</td>
<td>15/109 (13.8%)</td>
<td>3/54 (5.6%)</td>
</tr>
<tr>
<td>C&lt;sub&gt;t&lt;/sub&gt; median (range) *</td>
<td>36.5 (34.5-38.9)</td>
<td>36.8 (33.8-41.1)</td>
<td>37.2 (36.0-37.8)</td>
</tr>
</tbody>
</table>

Cell differentials definitions: Neutrophilic >50%, Lymphocytic effusion >50%, Eosinophilic >10%, Mixed- no predominant cell type. *when pleural fluid EBV detected